The Asbury Park Press reported on May 11:
Bristol-Myers Squibb Co., which employs about 7,700 workers in New Jersey, said today [May 11] it agreed to plead guilty to federal charges of making false statements to a government agency and pay a fine of up to $1 million in connection with its failed attempt to resolve a drug patent dispute last year.
IPBiz notes that the drug in question (Plavix) is an example of the chiral switch, the obviousness thereof may have been enhanced by the Supreme Court decision in KSR v. Teleflex.
The AP noted:
Bristol-Myers and Sanofi had initially promised Apotex they wouldn't sell Plavix without a label as a so-called "authorized generic" to undercut Apotex sales.